Friday, November 1307:00 – 09:302 h 30 minAd BoardBy invitation
Incyte
Incyte
2 sessions on Friday, November 13Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity. Our research and development efforts in Dermatology are focused on leveraging our cross-program knowledge to explore the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, and hidradenitis suppurativa.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For more information, visit Incyte.com and follow @Incyte.
Sessions at Dermatology Update — Fall 2026
2 sessionsFriday, November 1314:35 – 15:0530 minOpen Pres.
Quickfire Derm Cases with the JAK of all trades: Short cases. Sharp decisions.
Chair
Dr. Carrie Lynde
Dr. Carrie Lynde
During this session, attendees will hear concise real-life cases focused on Atopic Dermatitis and Vitiligo. The session will feature expert analysis, clinical decision-making process, and interactive engagement with the audience to foster practical learning.
Learning objectives
- Apply evidence-based principles to formulate personalized treatment plans in Atopic Dermatitis (AD) and Vitiligo (VIT)
- Assess the place of topical treatments in the AD and VIT treatment landscape
- Apply learnings from a collaborative case-based approach and joint problem-solving of actual AD and VIT cases
Atopic Dermatitis & EczemaPigmentation & Vitiligo